Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
Open accessThe DOI matches its Crossref record; 71 of the 73 references it cites were found in a registry or an index.
Abstract
Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood–brain barrier and systemic adverse effects. Intranasal administration offers a direct route to the brain via the nasal cavity’s olfactory and trigeminal pathways. However, nasal physiology can hinder drug absorption and limit bioavailability. Therefore, the physicochemical characteristics of formulations must be optimized by means of technological strategies. Among the strategies that have been explored, lipid-based nanosystems, particularly nanostructured lipid carriers, are promising in preclinical investigations with minimal toxicity and therapeutic efficacy due to their ability to overcome challenges associated with other nanocarriers. We review the studies of nanostructured lipid carriers for intranasal administration in the treatment of ATD. Currently, no drugs for intranasal administration in ATD have marketing approval, with only three candidates, insulin, rivastigmine and APH-1105, being clinically investigated. Further studies with different candidates will eventually confirm the potential of the intranasal route of administration in the treatment of ATD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 7 Innervation of the trigeminal nerve in the nasal cavity [39].](https://figures.cochat.ai/paper-figures/fd7eb22a56924927b531540e24dc7c54/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-7.jpg)


![Figure 3 (a) Anatomy of the nasal cavity, adapted from [32]. (b) Schematic representation of the olfactory region, adapted from [33].](https://figures.cochat.ai/paper-figures/6da7e5797e14487bb33d26eefca756c0/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-3.jpg)
![Figure 4 Factors affecting absorption through the nasal route [34].](https://figures.cochat.ai/paper-figures/688df23c98974d99bc31b371dfbc1de1/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-4.jpg)
![Figure 5 Mechanisms of drug absorption across the nasal epithelium [32].](https://figures.cochat.ai/paper-figures/938fb1209c844be380aea1ff4b583526/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-5.jpg)
![Figure 6 Intranasal transport of drugs through the olfactory route to the CNS by intracellular and extracellular routes [36].](https://figures.cochat.ai/paper-figures/01baa9b26e15440b8c7d6a51c5740cd5/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-6.jpg)
![Figure 8 Schematic representation of the structure of the nasal cavity and the mechanisms of drug absorption through the nasal mucosa to the brain. (A) Direct absorption mechanism through olfactory nerve and trigeminal route. (B) Indirect absorption mechanism by systemic route [42].](https://figures.cochat.ai/paper-figures/b5c3ba1682fd4acab06b49ecce101d7b/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-8.jpg)
![Figure 9 Lipid-based nanocarriers that have been explored for drug access to the brain from the nasal route [62].](https://figures.cochat.ai/paper-figures/3b2a6127a13e497fb48f67499281c055/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-9.jpg)
![Figure 10 Main differences between solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLCs) [66].](https://figures.cochat.ai/paper-figures/9c610ddcff6e4d19aa6dd9ab70cc3c29/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-10.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nanocarriers play a crucial role in increasing drug concentrations, slowing drug release, and achieving excellent bioavailability.401,406,407”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [406]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789 · cited 2×
“There were over 50 million ATD cases globally as of 2020 [4].”
BackgroundStrategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138 · cited 1×
“The BBB is a complex structure made up of endothelial cells sealed by tight junctions, pericytes, basement membrane and astrocytes that create a continuous barrier [24].”
BackgroundBurns, A., & Iliffe, S. (2009) · BMJ · doi:10.1136/bmj.b158 · Cited by 859 · cited 1×
“Around 6% of adults 65 and older are affected, with women being more frequently affected than males [9].”
BackgroundCilia and Mucociliary Clearance
Bustamante-Marin, X. M., & Ostrowski, L. E. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028241 · Cited by 830 · cited 1×
“When a formulation is administered via the nose, it has to go through mucociliary clearance, which will eliminate a part of the drug and which, together with the short residence time of the drug in the nasal cavity, will limit its absorption through the mucosa [44].”
BackgroundEvaluation of intranasal delivery route of drug administration for brain targeting
Erdő, F., Bors, L. A., Farkas, D., Bajza, Á., & Gizurarson, S. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.10.009 · Cited by 744 · cited 3×
“Intranasal transport of drugs through the olfactory route to the CNS by intracellular and extracellular routes [36].”
BackgroundInfluentialGlobal, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019
Li, X., Feng, X., Sun, X., Hou, N., Han, F., & Liu, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.937486 · Cited by 703 · cited 3×
“Dementia is more common in some parts of the world than others, with a prevalence of 4.7% in Central Europe and an 8.7% prevalence in North Africa and the Middle East [5,6].”
BackgroundInfluentialAgrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630 · cited 1×
“In addition, systemic administration may present other limitations such as binding to plasma proteins, low volume of distribution, delay in drug delivery to the brain through the blood, and systemic adverse effects, especially at the gastrointestinal level (such as nausea and vomiting) [21].”
BackgroundThe discovery of Alzheimer's disease
Hippius, H., & Neundörfer, G. (2003) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2003.5.1/hhippius · Cited by 516 · cited 2×
“e disease is named Alzheimer’s disease in h n r of Alois Alzheimer, a German psychiatrist and pathologist, who in 1906, first describ d th case of a 50-year-old woman with pr senile dementia [10].”
BackgroundClinical translation of nanomedicines: Challenges, opportunities, and keys
Younis, M. A., Tawfeek, H. M., Abdellatif, A. A. H., Abdel-Aleem, J. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114083 · Cited by 462 · cited 1×
“Finally, the lack of widely accepted international standards for regulating nanomedicines also poses a challenge [83].”
Background
Research works printed but not linked: 1
- Rajput, 2018, Fabrication of an ion-sensitive in situ gel loaded with nanostructured lipid carrier for nose to brain delivery of donepezil, Asian J. Pharm., 12, 293
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“401,406,407 Furthermore, the combination use of appropriate cholinesterase inhibitors, such as donepezil ( 4 ) and galantamine ( 6 ), or the combination of cholinesterase inhibitors with other neurologic drugs, metal chelators, or antioxidants, may yield surprising effects in the management of…”
BackgroundHuang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Mitochondria-Targeted Delivery Strategy of Dual-Loaded Liposomes for Alzheimer’s Disease Therapy
Vasileva, L. A., Gaynanova, G. A., Valeeva, F. G., Belyaev, G. P., Zueva, I. V., Bushmeleva, K., Sibgatullina, G., Samigullin, D., Vyshtakalyuk, A. B., Petrov, K. A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310494 · Cited by 51
Biomaterial strategies for regulating the neuroinflammatory response
Galindo, A. N., Rubio, D. A. F., & Hettiaratchi, M. H. (2024) · Materials Advances · doi:10.1039/d3ma00736g · Cited by 50
Peng, D., Liu, T., Lu, H., Zhang, L., Chen, H., Huang, Y., Hu, B., & Zhang, Q. (2024) · Theranostics · doi:10.7150/thno.103596 · Cited by 53
Metadata
- Authors
- Taléns-Visconti, R., de Julián-Ortiz, J. V., Vila-Busó, O., Diez-Sales, O., & Nácher, A.
- Affiliations
- Department of Pharmacy and Pharmaceutical Technology and Parasitology, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100 Valencia, Spain
- Molecular Topology and Drug Design Research Unit, Department of Physical Chemistry, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100 Valencia, Spain
- Universitat de València (ES)
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2023-05-03
- Volume
- 15
- Issue
- 5
- Pages
- 1399
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC10223127
- OpenAlex
- W4378516181
- Cited by
- 59
- References
- 73
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 19 · 2023: 6
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- intranasal administration, Alzheimer-type dementia, nanostructured lipid carriers, lipid-based nanosystems, blood-brain barrier, intranasal drug delivery, drug bioavailability, nanocarriers, rivastigmine, insulin, Alzheimer's disease treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications. https://app.cochat.ai/papers/10.3390/pharmaceutics15051399
- The paper
- Taléns-Visconti, R., de Julián-Ortiz, J. V., Vila-Busó, O., Diez-Sales, O., & Nácher, A. (2023). Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications. Pharmaceutics. https://doi.org/10.3390/pharmaceutics15051399
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.